Petrelintide’s phase 1 data put a long-acting amylin analogue into the weight-loss race

What happened

Petrelintide, a long-acting analogue of the pancreatic peptide hormone amylin, was evaluated in randomized, placebo-controlled single- and multiple-ascending-dose studies. The July 2026 journal record describes weekly subcutaneous dosing and a 16-week escalation cohort in adults with overweight or obesity.

What the studies found

Investigators reported slow absorption, an approximate 10-day half-life and dose-proportional exposure at steady state. In the longer cohort, body-weight reduction reached as much as 8.6% after 16 weeks. Gastrointestinal events were the most common treatment-emergent problems; most were mild, while one participant discontinued after gastrointestinal events.

Evidence check

Phase 1 trials primarily characterize safety, exposure and biological activity. The cohorts were small and not designed to establish comparative effectiveness or long-term safety. Maximum observed weight change in an early dose-escalation study should not be read as the expected result for a general population.

Why it matters

Amylin biology offers a peptide pathway distinct from GLP-1, potentially widening future combination and tolerability strategies. The competitive question is no longer whether the molecule moves weight in an early trial; it is whether larger studies can reproduce meaningful loss with a differentiated adverse-event profile. This report does not support unsupervised use.